MDWD vs NAGE
Mediwound Ltd. and Niagen Bioscience, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MDWD | NAGE |
|---|---|---|
| Revenue | $17.0M | $129.4M |
| Net income | $-23.9M | $17.4M |
| Gross margin | 19.2% | 64.3% |
| Net margin | −140.8% | 13.4% |
| Return on equity | — | 28.3% |
| Diluted EPS | −$2.10 | $0.20 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-21.6M | $-21.2M |
| Equity | — | $76.5M |
| Net debt / equity | — | — |
| Current ratio | 2.33× | 4.86× |
| Revenue CAGR 5y | −4.9% | 16.9% |
| Profit CAGR 5y | — | — |
NAGE bills 7.6× the revenue of MDWD, and MDWD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | MDWD | NAGE |
|---|---|---|
| FY2025 | $17.0M | $129.4M |
| FY2024 | $20.2M | $99.6M |
| FY2023 | $18.7M | $83.6M |
| FY2022 | $26.5M | $72.0M |
| FY2021 | $23.8M | $67.4M |
| FY2020 | $21.8M | $59.3M |
| FY2019 | $31.8M | $46.3M |
| FY2018 | $3.4M | $31.6M |
| FY2017 | $2.5M | $21.2M |
| FY2016 | $1.6M | $21.7M |
Net income by year
Bottom line
| Fiscal year | MDWD | NAGE |
|---|---|---|
| FY2025 | $-23.9M | $17.4M |
| FY2024 | $-30.2M | $8.6M |
| FY2023 | $-6.7M | $-4.9M |
| FY2022 | $-19.6M | $-16.5M |
| FY2021 | $-13.6M | $-27.1M |
| FY2020 | $-9.2M | $-19.9M |
| FY2019 | $5.0M | $-32.1M |
| FY2018 | $-1.1M | $-33.3M |
| FY2017 | $-22.1M | $-11.4M |
| FY2016 | $-18.9M | $-2.9M |
Advertisement
AdSense · Rectangle 336×280
More in this industry